Education
About Us
Working with TipRanks
Follow Us
Applied Therapeutics Inc (APLT)
NASDAQ:APLT
APLT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.43 - $10.62
Previous CloseN/A
Volume3.84M
Average Volume (3M)2.41M
Market Cap
$66.68M
Enterprise Value$1.13B
Total Cash (Recent Filing)$49.90M
Total Debt (Recent Filing)$777.00K
Price to Earnings (P/E)―
Beta0.11
Next Earnings
May 08, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding116,356,476
10 Day Avg. Volume1,605,763
30 Day Avg. Volume2,414,676
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.67
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap16.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit117.22
Enterprise Value/Ebitda-12.26
Forecast
1Y Price Target
$1.50Price Target Upside167.86% Upside
Rating ConsensusHold
Number of Analyst Covering0
---
Bulls Say, Bears Say
Bulls Say
Community SupportGovorestat still has a lot of support from the galactosemia KOL community and patient advocates, highlighting the unmet need.
Leadership ChangeAPLT has announced John H. Johnson, an industry veteran with more than 40 years of experience, will serve as Executive Chairman, and Les Funtleyder, who is currently the CFO and has served on APLT's board, will serve as interim CEO.
SORD Program ProgressThe clinical trial in SORD met its co-primary endpoints, suggesting a potentially stronger data package.
Bears Say
Approval RisksThe likelihood of non-approval for govorestat in galactosemia has increased, affecting the overall assessment.
Market UncertaintyDowngrading Shares to Market Perform Due to Increased Uncertainty Around Govorestat's Future and Limited Cash.
Regulatory ChallengesAPLT received a CRL for govorestat in classic galactosemia, which was followed by a warning letter from the FDA.
---
Ownership Overview
14.95% Insiders
8.56% Mutual Funds
0.27% Other Institutional Investors
59.87% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APLT FAQ
What was Applied Therapeutics Inc’s price range in the past 12 months?
Applied Therapeutics Inc lowest stock price was $0.43 and its highest was $10.62 in the past 12 months.
What is Applied Therapeutics Inc’s market cap?
Applied Therapeutics Inc’s market cap is $66.68M.
When is Applied Therapeutics Inc’s upcoming earnings report date?
Applied Therapeutics Inc’s upcoming earnings report date is May 08, 2025 which is in 43 days.
How were Applied Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Applied Therapeutics Inc overvalued?
According to Wall Street analysts Applied Therapeutics Inc’s price is currently Undervalued.
Does Applied Therapeutics Inc pay dividends?
Applied Therapeutics Inc does not currently pay dividends.
What is Applied Therapeutics Inc’s EPS estimate?
Applied Therapeutics Inc’s EPS estimate is -0.18.
How many shares outstanding does Applied Therapeutics Inc have?
Applied Therapeutics Inc has 116,356,476 shares outstanding.
What happened to Applied Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Applied Therapeutics Inc?
Currently, no hedge funds are holding shares in APLT
---
Applied Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.50 (167.86% Upside)
$1.50 (167.86% Upside)
Blogger Sentiment
Bullish
APLT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 7.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $94.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.71%
12-Months-Change
Fundamentals
Return on Equity
-3179.06%
Trailing 12-Months
Asset Growth
135.79%
Trailing 12-Months
Company Description
Applied Therapeutics Inc
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
---
APLT Stock 12 Month Forecast
Average Price Target
$1.50
▲(167.86% Upside)
Technical Analysis
Xoma
―
RedHill Biopharma
―
Ocular Therapeutix
―
Protagonist Therapeutics
―
Annovis Bio
―
Best Analysts Covering APLT
1 Year
1 Year Success Rate
11/32 ratings generated profit
1 Year Average Return
+56.02%
reiterated a buy rating 4 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 34.38% of your transactions generating a profit, with an average return of +56.02% per trade.
---